Arvinas doses first patient in ARV-6723 Phase 1/2 trial

September 28, 2026 7:00 AM

Arvinas, Inc. (Nasdaq: ARVN) announced that the first participant has been dosed in a Phase 1/2 clinical trial of ARV-6723 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found